It is time to reconsider leukoreduction of whole blood for use in patients with life‐threatening hemorrhage
PCS consults for Hemanext, Cerus, is on the scientific advisory board for Haima and Octapharma, and is a co-founder and chief medical officer for Kalocyte. EMB reports personal fees and non-financial support from Grifols, Abbott, UpToDate, Tegus, and Health Advances outside of the submitted work. EMB is a co-investigator on a US government-funded clinical trial evaluating Mirasol Pathogen Reduction Technology. CSC is on the scientific advisory board of Fresenius-Kabi and is a consultant for Quidel OrthoClinical. MHY is on the scientific advisory board for Hemanext and has given paid lectures for Terumo BCT and Grifols. The remaining authors declare no conflict of interest.
Authors
- Andrew Beckett (ORCID: https://orcid.org/0000-0002-4943-9415)
- Mark H. Yazer (ORCID: https://orcid.org/0000-0001-6740-2758)
- Philip Charles Spinella (ORCID: https://orcid.org/0000-0003-1721-0541)
- Evan M. Bloch (ORCID: https://orcid.org/0000-0001-8181-9517)
- Daniela Hermelin (ORCID: https://orcid.org/0000-0001-9099-6021)
- Jennifer M. Gurney (ORCID: https://orcid.org/0000-0002-0451-1137)
- Claudia S. Cohn (ORCID: https://orcid.org/0000-0001-9847-0470)
- P. Andrew (ORCID: https://orcid.org/0000-0003-0357-0597)
Institutions
- University of Minnesota (US)
- Johns Hopkins University (US)
- Uniformed Services University of the Health Sciences (US)
- University of Pittsburgh (US)
- University of Toronto (CA)
- Canadian Armed Forces (CA)
- Johns Hopkins Medicine (US)
- American Association of Blood Banks (US)
- Community Impact (US)
- Saint Louis University (US)
Publication Details
- Journal
- Transfusion
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1111/trf.18047
- Citations
- 9
- Primary Topic
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Type
- article
- Field-Weighted Citation Impact
- 3.80